CGRP Monoclonal Antibodies for Migraine Linked to Fracture Risk

Text
A study published in Medscape links CGRP monoclonal antibodies (Mab) for migraine treatment to an increased risk of fractures, according to a report from Medscape. The findings, based on a retrospective analysis of patient data, suggest that long-term use of these medications may be associated with a higher likelihood of bone fractures, particularly in older adults.

Text
The research, conducted by a team of researchers at a university-affiliated medical center, analyzed health records of over 15,000 patients who had received CGRP Mab therapy for chronic migraines between 2018 and 2025. The study found that individuals taking these drugs for more than two years had a 12% higher risk of fractures compared to those who did not receive the treatment. The risk was most pronounced in patients over the age of 65, with hip and vertebral fractures showing the greatest increase.

Text
CGRP Mab drugs, including erenumab and fremanezumab, work by blocking calcitonin gene-related peptide, a molecule involved in migraine pain signaling. These medications have become a mainstay for patients with frequent migraines, offering an alternative to traditional treatments like triptans and beta-blockers. However, the new findings highlight potential long-term side effects that may not have been fully understood at the time of their initial approval.

Text
“Patients and healthcare providers should be aware of this association, but it’s important to note that the absolute risk remains relatively low,” said Dr. Emily Thompson, a neurologist at the University of California, San Francisco, who was not involved in the study. “The benefits of CGRP Mab therapy for managing severe migraines still outweigh the risks for many patients, but ongoing monitoring is necessary.”

Text
The study’s authors emphasized that the observed link between CGRP Mabs and fractures does not prove causation. They hypothesized that the medications might interfere with bone remodeling processes, though further research is needed to confirm this mechanism. Additionally, the study did not account for factors such as vitamin D levels, physical activity, or pre-existing osteoporosis, which could influence fracture risk.

Text
Health authorities have not yet issued formal guidance in response to the findings. The U.S. Food and Drug Administration (FDA) stated in a statement that it is “reviewing the data” but reiterated that CGRP Mabs remain a “valuable treatment option” for eligible patients. The European Medicines Agency (EMA) has not commented publicly on the study.

Text
Patients currently taking CGRP Mab therapy are advised to discuss their individual risks with their healthcare providers. Doctors may consider bone density screenings or recommend calcium and vitamin D supplementation as preventive measures. For those experiencing significant side effects, alternative treatments may be explored.

Text
The study adds to a growing body of research examining the long-term safety of CGRP Mab drugs. Earlier studies have raised concerns about potential cardiovascular risks, though these findings have not been consistently replicated. The latest results underscore the need for continued post-market surveillance of medications, particularly those used for chronic conditions.

Text
Experts caution against overinterpreting the data. “This is an observational study, and there may be confounding factors we haven’t accounted for,” said Dr. Michael Reynolds, a pharmacologist at the Mayo Clinic. “More rigorous trials are needed to determine whether the risk is directly tied to the medication or other variables.”

Text
For now, the medical community remains divided on the implications of the findings. While some clinicians advocate for heightened vigilance, others argue that the benefits of CGRP Mab therapy for severe migraine cases justify the risks. Patients are encouraged to weigh their options carefully and maintain open communication with their healthcare teams.

Text
The study was published in Medscape on June 9, 2026, and is available for review on the platform. Researchers have called for larger, randomized trials to clarify the relationship between CGRP Mab use and fracture risk. Until then, the findings serve as a reminder of the complex trade-offs involved in managing chronic conditions with novel therapies.